Antibiotic Development: Lessons from the Past and Future Opportunities
The challenge of antimicrobial resistance is broadly appreciated by the clinical and scientific communities. To assess progress in the development of medical countermeasures to combat bacterial infections, we deployed information gleaned from clinical trials conducted from 2000 to 2021. Whereas priv...
Gespeichert in:
| Veröffentlicht in: | Pharmaceutical research 2024-05, Vol.41 (5), p.839-848 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 848 |
|---|---|
| container_issue | 5 |
| container_start_page | 839 |
| container_title | Pharmaceutical research |
| container_volume | 41 |
| creator | Kinch, Michael S. Kraft, Zachary Schwartz, Tyler |
| description | The challenge of antimicrobial resistance is broadly appreciated by the clinical and scientific communities. To assess progress in the development of medical countermeasures to combat bacterial infections, we deployed information gleaned from clinical trials conducted from 2000 to 2021. Whereas private sector interest in cancer grew dramatically over this period, activity to combat bacterial infections remained stagnant. The comparative ambivalence to antimicrobial resistance is reflected in the number of investigative drugs under clinical investigation, their stage of development and most troublingly, a declining number of organizations that are actively involved in the development of new products to treat bacterial infections. This drop reflects the exits of many companies that had previously developed antibacterial agents. |
| doi_str_mv | 10.1007/s11095-024-03694-2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_3031131834</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A795155674</galeid><sourcerecordid>A795155674</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-66be09d61c3c9c1a61b4a7b562eb5af61b0cfd6545ab42500ebf45811307115f3</originalsourceid><addsrcrecordid>eNp9kU9rFTEUxYNY7LP6BVzIgJtups2d_JmJu0f1qfCgLhTchUzmTk2ZScYkI_jtm-erFkUki5B7f-dwwiHkBdALoLS9TABUiZo2vKZMKl43j8gGRMtqRfmXx2RD27LqWg6n5GlKt5TSDhR_Qk5ZJySIDjZkt_XZ9S5kZ6s3-B2nsMzo8-tqjykFn6oxhrnKX7H6aFKujB-q3ZrXiNX1soSYV--yw_SMnIxmSvj8_j4jn3dvP129r_fX7z5cbfe1ZYrlWsoeqRokWGaVBSOh56bthWywF2YsT2rHQQouTM8bQSn2Iy85gdEWQIzsjJwffZcYvq2Ysp5dsjhNxmNYk2aUFRg6xgv66i_0NqzRl3SFEgpY1yn5QN2YCbXzY8jR2IOp3rZKgBCyPXhd_IMqZ8DZ2eBxdGX-h6A5CmwMKUUc9RLdbOIPDVQfytPH8nQpT_8sTzdF9PI-8drPOPyW_GqrAOwIpLLyNxgfvvQf2ztSpKHt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3059138896</pqid></control><display><type>article</type><title>Antibiotic Development: Lessons from the Past and Future Opportunities</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kinch, Michael S. ; Kraft, Zachary ; Schwartz, Tyler</creator><creatorcontrib>Kinch, Michael S. ; Kraft, Zachary ; Schwartz, Tyler</creatorcontrib><description>The challenge of antimicrobial resistance is broadly appreciated by the clinical and scientific communities. To assess progress in the development of medical countermeasures to combat bacterial infections, we deployed information gleaned from clinical trials conducted from 2000 to 2021. Whereas private sector interest in cancer grew dramatically over this period, activity to combat bacterial infections remained stagnant. The comparative ambivalence to antimicrobial resistance is reflected in the number of investigative drugs under clinical investigation, their stage of development and most troublingly, a declining number of organizations that are actively involved in the development of new products to treat bacterial infections. This drop reflects the exits of many companies that had previously developed antibacterial agents.</description><identifier>ISSN: 0724-8741</identifier><identifier>ISSN: 1573-904X</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1007/s11095-024-03694-2</identifier><identifier>PMID: 38561581</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Animals ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; Antibiotics ; Antimicrobial resistance ; Bacteria ; Bacterial infections ; Bacterial Infections - drug therapy ; Bacterial Infections - microbiology ; Biochemistry ; Biomedical and Life Sciences ; Biomedical Engineering and Bioengineering ; Biomedicine ; Clinical trials ; Clinical Trials as Topic ; Drug development ; Drug Development - methods ; Drug Development - trends ; Drug Discovery - methods ; Drug Discovery - trends ; Drug resistance ; Drug resistance in microorganisms ; Drug Resistance, Bacterial ; Federal regulation ; Health aspects ; Humans ; Infection ; Medical Law ; Pharmaceuticals ; Pharmacology/Toxicology ; Pharmacy ; Review Article ; Tetracycline ; Tetracyclines</subject><ispartof>Pharmaceutical research, 2024-05, Vol.41 (5), p.839-848</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>COPYRIGHT 2024 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c393t-66be09d61c3c9c1a61b4a7b562eb5af61b0cfd6545ab42500ebf45811307115f3</cites><orcidid>0000-0003-3939-3756</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11095-024-03694-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11095-024-03694-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38561581$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kinch, Michael S.</creatorcontrib><creatorcontrib>Kraft, Zachary</creatorcontrib><creatorcontrib>Schwartz, Tyler</creatorcontrib><title>Antibiotic Development: Lessons from the Past and Future Opportunities</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><addtitle>Pharm Res</addtitle><description>The challenge of antimicrobial resistance is broadly appreciated by the clinical and scientific communities. To assess progress in the development of medical countermeasures to combat bacterial infections, we deployed information gleaned from clinical trials conducted from 2000 to 2021. Whereas private sector interest in cancer grew dramatically over this period, activity to combat bacterial infections remained stagnant. The comparative ambivalence to antimicrobial resistance is reflected in the number of investigative drugs under clinical investigation, their stage of development and most troublingly, a declining number of organizations that are actively involved in the development of new products to treat bacterial infections. This drop reflects the exits of many companies that had previously developed antibacterial agents.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antimicrobial resistance</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacterial Infections - microbiology</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering and Bioengineering</subject><subject>Biomedicine</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Drug development</subject><subject>Drug Development - methods</subject><subject>Drug Development - trends</subject><subject>Drug Discovery - methods</subject><subject>Drug Discovery - trends</subject><subject>Drug resistance</subject><subject>Drug resistance in microorganisms</subject><subject>Drug Resistance, Bacterial</subject><subject>Federal regulation</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Infection</subject><subject>Medical Law</subject><subject>Pharmaceuticals</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Review Article</subject><subject>Tetracycline</subject><subject>Tetracyclines</subject><issn>0724-8741</issn><issn>1573-904X</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9rFTEUxYNY7LP6BVzIgJtups2d_JmJu0f1qfCgLhTchUzmTk2ZScYkI_jtm-erFkUki5B7f-dwwiHkBdALoLS9TABUiZo2vKZMKl43j8gGRMtqRfmXx2RD27LqWg6n5GlKt5TSDhR_Qk5ZJySIDjZkt_XZ9S5kZ6s3-B2nsMzo8-tqjykFn6oxhrnKX7H6aFKujB-q3ZrXiNX1soSYV--yw_SMnIxmSvj8_j4jn3dvP129r_fX7z5cbfe1ZYrlWsoeqRokWGaVBSOh56bthWywF2YsT2rHQQouTM8bQSn2Iy85gdEWQIzsjJwffZcYvq2Ysp5dsjhNxmNYk2aUFRg6xgv66i_0NqzRl3SFEgpY1yn5QN2YCbXzY8jR2IOp3rZKgBCyPXhd_IMqZ8DZ2eBxdGX-h6A5CmwMKUUc9RLdbOIPDVQfytPH8nQpT_8sTzdF9PI-8drPOPyW_GqrAOwIpLLyNxgfvvQf2ztSpKHt</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Kinch, Michael S.</creator><creator>Kraft, Zachary</creator><creator>Schwartz, Tyler</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3939-3756</orcidid></search><sort><creationdate>20240501</creationdate><title>Antibiotic Development: Lessons from the Past and Future Opportunities</title><author>Kinch, Michael S. ; Kraft, Zachary ; Schwartz, Tyler</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-66be09d61c3c9c1a61b4a7b562eb5af61b0cfd6545ab42500ebf45811307115f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antimicrobial resistance</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacterial Infections - microbiology</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering and Bioengineering</topic><topic>Biomedicine</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Drug development</topic><topic>Drug Development - methods</topic><topic>Drug Development - trends</topic><topic>Drug Discovery - methods</topic><topic>Drug Discovery - trends</topic><topic>Drug resistance</topic><topic>Drug resistance in microorganisms</topic><topic>Drug Resistance, Bacterial</topic><topic>Federal regulation</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Infection</topic><topic>Medical Law</topic><topic>Pharmaceuticals</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Review Article</topic><topic>Tetracycline</topic><topic>Tetracyclines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kinch, Michael S.</creatorcontrib><creatorcontrib>Kraft, Zachary</creatorcontrib><creatorcontrib>Schwartz, Tyler</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kinch, Michael S.</au><au>Kraft, Zachary</au><au>Schwartz, Tyler</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotic Development: Lessons from the Past and Future Opportunities</atitle><jtitle>Pharmaceutical research</jtitle><stitle>Pharm Res</stitle><addtitle>Pharm Res</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>41</volume><issue>5</issue><spage>839</spage><epage>848</epage><pages>839-848</pages><issn>0724-8741</issn><issn>1573-904X</issn><eissn>1573-904X</eissn><abstract>The challenge of antimicrobial resistance is broadly appreciated by the clinical and scientific communities. To assess progress in the development of medical countermeasures to combat bacterial infections, we deployed information gleaned from clinical trials conducted from 2000 to 2021. Whereas private sector interest in cancer grew dramatically over this period, activity to combat bacterial infections remained stagnant. The comparative ambivalence to antimicrobial resistance is reflected in the number of investigative drugs under clinical investigation, their stage of development and most troublingly, a declining number of organizations that are actively involved in the development of new products to treat bacterial infections. This drop reflects the exits of many companies that had previously developed antibacterial agents.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>38561581</pmid><doi>10.1007/s11095-024-03694-2</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-3939-3756</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0724-8741 |
| ispartof | Pharmaceutical research, 2024-05, Vol.41 (5), p.839-848 |
| issn | 0724-8741 1573-904X 1573-904X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3031131834 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Animals Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotics Antimicrobial resistance Bacteria Bacterial infections Bacterial Infections - drug therapy Bacterial Infections - microbiology Biochemistry Biomedical and Life Sciences Biomedical Engineering and Bioengineering Biomedicine Clinical trials Clinical Trials as Topic Drug development Drug Development - methods Drug Development - trends Drug Discovery - methods Drug Discovery - trends Drug resistance Drug resistance in microorganisms Drug Resistance, Bacterial Federal regulation Health aspects Humans Infection Medical Law Pharmaceuticals Pharmacology/Toxicology Pharmacy Review Article Tetracycline Tetracyclines |
| title | Antibiotic Development: Lessons from the Past and Future Opportunities |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T09%3A28%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotic%20Development:%20Lessons%20from%20the%20Past%20and%20Future%20Opportunities&rft.jtitle=Pharmaceutical%20research&rft.au=Kinch,%20Michael%20S.&rft.date=2024-05-01&rft.volume=41&rft.issue=5&rft.spage=839&rft.epage=848&rft.pages=839-848&rft.issn=0724-8741&rft.eissn=1573-904X&rft_id=info:doi/10.1007/s11095-024-03694-2&rft_dat=%3Cgale_proqu%3EA795155674%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3059138896&rft_id=info:pmid/38561581&rft_galeid=A795155674&rfr_iscdi=true |